ZNF329 Inhibitors
ZNF329 inhibitors encompass a range of chemical compounds that indirectly influence the activity of the zinc finger protein ZNF329 by targeting various cellular pathways and processes. For instance, proteasome inhibitors like MG132 and Bortezomib result in the buildup of ubiquitinated proteins. This accumulation can impact the function of ZNF329 if it is involved in protein turnover by binding to and regulating these ubiquitinated substrates, thereby indirectly inhibiting its regulatory role. Autophagy inhibitors such as Chloroquine indirectly affect ZNF329 by interfering with the degradation pathways that may be essential for the turnover of complexes involving ZNF329, thus inhibiting its function.
Furthermore, inhibitors of specific kinases and phosphatases, including LY294002 and U0126, target the PI3K/AKT and MAPK/ERK pathways, respectively. The inhibition of these pathways can lead to reduced phosphorylation of various proteins, potentially altering the activity of ZNF329 if it is implicated in the regulation of these phosphorylation events. Similarly, the mTOR pathway, targeted by compounds like Rapamycin, plays a critical role in protein synthesis and cell growth, processes that ZNF329 might regulate. By inhibiting mTOR, Rapamycin could indirectly inhibit ZNF329's function in these pathways. Additionally, epigenetic modulators such as Sodium Butyrate and Trichostatin A alter gene expression patterns and may affect the transcriptional control exerted by ZNF329, leading to an indirect inhibition of its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A peptide aldehyde that inhibits proteasomes, leading to the accumulation of ubiquitinated proteins. This can indirectly inhibit ZNF329 by disrupting the degradation process that ZNF329 might be involved in, thereby altering its turnover and regulatory functions. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
An autophagy inhibitor that raises lysosomal pH, preventing the degradation of autophagosomes, and could affect ZNF329 by interrupting the autophagic turnover of cellular components that ZNF329 might regulate. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor which can reduce AKT phosphorylation, potentially decreasing the activity of downstream proteins regulated by the PI3K/AKT pathway, in which ZNF329 might play a regulatory role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor which blocks the MAPK/ERK pathway, potentially altering the activity of transcription factors and other proteins that ZNF329 might influence. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can suppress the p38-mediated signaling pathway, possibly affecting the cellular processes that ZNF329 is involved in by altering the phosphorylation state of target molecules. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the JNK signaling pathway. By inhibiting JNK, it can affect the activity of transcription factors and other proteins that ZNF329 might interact with or regulate. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that, like MG132, can increase the levels of ubiquitinated proteins, potentially affecting ZNF329 by altering protein turnover and regulatory mechanisms it might be involved with. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which can disrupt the mTOR signaling pathway, affecting protein synthesis and other cellular processes that ZNF329 might influence. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that can prevent the activation of AKT, leading to changes in downstream signaling pathways and potentially affecting the activity of ZNF329. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
A histone deacetylase inhibitor that can alter chromatin structure and gene expression, potentially affecting ZNF329 by changing the transcriptional landscape of the genes it regulates. | ||||||